110 related articles for article (PubMed ID: 6195752)
1. Individual levels of plasma alpha 2-antiplasmin and alpha 2-macroglobulin during the normal menstrual cycle and in women on oral contraceptives low in oestrogen.
Jespersen J; Sidelmann J
Thromb Haemost; 1983 Aug; 50(2):581-5. PubMed ID: 6195752
[TBL] [Abstract][Full Text] [Related]
2. Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen.
Jespersen J; Kluft C
Scand J Clin Lab Invest; 1982 Nov; 42(7):563-6. PubMed ID: 6818678
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
Schneider WH; Schmid R; Spona J
Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle.
Jespersen J; Kluft C
Thromb Haemost; 1986 Jun; 55(3):388-9. PubMed ID: 3092396
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
6. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
7. [Oral contraceptive agents and the fibrinolytic system].
Nalbanski B; Kamenov V
Akush Ginekol (Sofiia); 1989; 28(6):51-5. PubMed ID: 2483796
[TBL] [Abstract][Full Text] [Related]
8. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
9. alpha 2-Antiplasmin and alpha 2-macroglobulin--the main inhibitors of fibrinolysis--during the menstrual cycle, pregnancy, delivery, and treatment with oral contraceptives.
Wallmo L; Gyzander E; Karlsson K; Lindstedt G; Rådberg T; Teger-Nilsson AC
Acta Obstet Gynecol Scand; 1982; 61(5):417-22. PubMed ID: 6186117
[TBL] [Abstract][Full Text] [Related]
10. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
11. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
Jespersen J
Gynecol Obstet Invest; 1983; 15(5):266-74. PubMed ID: 6852646
[TBL] [Abstract][Full Text] [Related]
12. Changes in alpha 1-antitrypsin (AAT) and alpha 2-macroglobulin serum concentrations during treatment with oral estro-progestogens.
Paternoster D; Maggino T; Valente S; Pengo V; Ongaro G
Quad Sclavo Diagn; 1982 Jun; 18(2):132-9. PubMed ID: 6188185
[No Abstract] [Full Text] [Related]
13. [Hypophyseal reaction state during oral contraceptiva (author's transl)].
Gitsch E; Schneider WH; Schmid R; Spona J
Wien Klin Wochenschr; 1981 Oct; 93(19):599-601. PubMed ID: 6798764
[TBL] [Abstract][Full Text] [Related]
14. The effect of oral contraceptives on coagulation and fibrinolytic parameters in the Chinese--a prospective study.
Wong V; Chan TK; Chan V; Tso SC; Todd D; Ma HK
Thromb Haemost; 1982 Dec; 48(3):263-5. PubMed ID: 7164016
[TBL] [Abstract][Full Text] [Related]
15. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters.
Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Kuhl H
Contraception; 2008 Nov; 78(5):384-91. PubMed ID: 18929735
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
17. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
18. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen.
Jespersen J; Kluft C
Thromb Haemost; 1982 Dec; 48(3):283-5. PubMed ID: 7164018
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral contraceptive (ethinyl estradiol and d-norgestrel) on serum prolactin-oestradiol and progesterone levels.
Erodogan M; Inal A; Ozgu M; Beksac MS; Ergurbuz I
Acta Reprod Turc; 1980 Jan; 1(3):85-91. PubMed ID: 12262090
[TBL] [Abstract][Full Text] [Related]
20. Effect of four oral contraceptives on hemostatic parameters.
Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H
Contraception; 2004 Aug; 70(2):97-106. PubMed ID: 15288212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
